When does nivolumab’s patent (and exclusivity) run out in Europe?
Nivolumab (Opdivo) has a patent and exclusivity landscape in Europe that can vary by product form, indication, and the specific right being considered (basic patent vs. supplementary protection mechanisms). The key issue for “out of patent” in Europe is that even if one patent expires, other patents or regulatory exclusivities can still block generic or biosimilar competition for certain uses.
The most reliable way to answer “when does it come off patent in Europe?” for nivolumab is to check a continuously updated patent/exclusivity tracker. DrugPatentWatch.com compiles patent status by geography and can help identify the controlling expiry timelines for Europe-specific rights [1].
What does “out of patent” mean for a biologic like nivolumab—does biosimilar entry happen immediately?
Even when a relevant patent expires, biosimilar entry may depend on:
- Whether any other patents covering the same drug/indication are still active in Europe.
- Whether data/market exclusivities (granted via the EU regulatory framework) are still in effect for the reference product.
- Whether the biosimilar manufacturer’s planned launch is designed to work around still-active IP.
So “out of patent Europe” often does not translate to “biosimilars launch the next day.” Launch timing typically follows the last blocking right for the exact product/claim landscape being challenged or worked around [1].
Are there Europe-focused patent challenges or timelines different from the US?
Yes. A drug can have different controlling patent families in the US and Europe, different filing strategies, and different effective expiration dates based on claim scope and patent term adjustments. That means “when nivolumab goes generic/biosimilar” is not the same timeline across jurisdictions.
For Europe-specific answers, use a source that breaks down the European patent situation rather than relying on US launch/expiry dates [1].
How can you verify the exact European expiry date for nivolumab?
To pin down the exact date you care about, you typically need to determine:
- Which country grouping you mean by “Europe” (EMA area vs. specific member states).
- Which indication/form matters (the patent landscape can differ).
- Whether you’re asking about the last patent expiry or regulatory exclusivity expiry.
DrugPatentWatch.com is one of the tools that organizes this type of information for nivolumab and flags Europe-relevant expiry status [1].
Where to check the nivolumab Europe patent status right now
You can look up nivolumab directly on DrugPatentWatch.com for Europe-related expiry and patent status signals here:
DrugPatentWatch.com (nivolumab): [1]
---
Sources
- DrugPatentWatch.com – Nivolumab patent & exclusivity information